Page last updated: 2024-08-24

valsartan and Glucose Metabolic Disorder

valsartan has been researched along with Glucose Metabolic Disorder in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	2 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Blaak, EE; Diamant, M; Goossens, GH; Moors, CC; van der Zijl, NJ	1
Califf, RM; Giles, T; Haffner, SM; Hernandez, AF; Krum, H; Leiter, LA; Martinez, FA; Mazzone, T; McMurray, JJ; Rutten, GE; Standl, E; Sun, JL; Thomas, L; Tognoni, G; Wong, YW	1

Trials

2 trial(s) available for valsartan and Glucose Metabolic Disorder

Article	Year
The effects of long-term valsartan treatment on skeletal muscle fatty acid handling in humans with impaired glucose metabolism. The Journal of clinical endocrinology and metabolism, 2013, Volume: 98, Issue:5 Topics: Angiotensin II Type 1 Receptor Blockers; Biopsy; Carbon Radioisotopes; Double-Blind Method; Fasting; Fatty Acids, Nonesterified; Female; Forearm; Gene Expression Regulation; Glucose Metabolism Disorders; Humans; Lipid Metabolism; Male; Muscle Proteins; Muscle, Skeletal; Oxidation-Reduction; Postprandial Period; RNA, Messenger; Tetrazoles; Tritium; Valine; Valsartan	2013
Predictors of incident heart failure hospitalizations among patients with impaired glucose tolerance: insight from the Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research study. Circulation. Heart failure, 2013, Volume: 6, Issue:2 Topics: Adiposity; Aged; Albuminuria; Biomarkers; Blood Glucose; Creatinine; Cyclohexanes; Double-Blind Method; Female; Glucose Metabolism Disorders; Heart Failure; Hospitalization; Humans; Hypoglycemic Agents; Incidence; Linear Models; Male; Middle Aged; Multivariate Analysis; Nateglinide; Nonlinear Dynamics; Obesity, Abdominal; Phenylalanine; Proportional Hazards Models; Prospective Studies; Risk Assessment; Risk Factors; Tetrazoles; Time Factors; Treatment Outcome; Valine; Valsartan; Waist Circumference	2013

Article

Year

The effects of long-term valsartan treatment on skeletal muscle fatty acid handling in humans with impaired glucose metabolism.

The Journal of clinical endocrinology and metabolism, 2013, Volume: 98, Issue:5

Topics: Angiotensin II Type 1 Receptor Blockers; Biopsy; Carbon Radioisotopes; Double-Blind Method; Fasting; Fatty Acids, Nonesterified; Female; Forearm; Gene Expression Regulation; Glucose Metabolism Disorders; Humans; Lipid Metabolism; Male; Muscle Proteins; Muscle, Skeletal; Oxidation-Reduction; Postprandial Period; RNA, Messenger; Tetrazoles; Tritium; Valine; Valsartan

2013

Predictors of incident heart failure hospitalizations among patients with impaired glucose tolerance: insight from the Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research study.

Circulation. Heart failure, 2013, Volume: 6, Issue:2

Topics: Adiposity; Aged; Albuminuria; Biomarkers; Blood Glucose; Creatinine; Cyclohexanes; Double-Blind Method; Female; Glucose Metabolism Disorders; Heart Failure; Hospitalization; Humans; Hypoglycemic Agents; Incidence; Linear Models; Male; Middle Aged; Multivariate Analysis; Nateglinide; Nonlinear Dynamics; Obesity, Abdominal; Phenylalanine; Proportional Hazards Models; Prospective Studies; Risk Assessment; Risk Factors; Tetrazoles; Time Factors; Treatment Outcome; Valine; Valsartan; Waist Circumference

2013